A Phase 2a Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of CAD-1883 Oral Treatment in Adults With Essential Tremor
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2019
At a glance
- Drugs CAD-1883 (Primary)
- Indications Essential tremor
- Focus Adverse reactions
- Sponsors Cadent Therapeutics
- 14 Dec 2018 Planned End Date changed from 1 May 2019 to 1 Jun 2019.
- 14 Dec 2018 Planned primary completion date changed from 1 Apr 2019 to 1 May 2019.
- 15 Nov 2018 Status changed from not yet recruiting to recruiting, as reported in a Saniona media release.